Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell -engaging therapies. Cancer J. 2014;20(2):119 -22. doi: 10.1097/PPO.0000000000000035. 50. Mezquita L, Charrier M, Faivre L, Dupraz L, Luezac B, Remon J, et al. Prognostic value of HLA -A2 status in advanced non -small cell lung cancer patients . Lung Cancer 112 (2017) 10 - 15. 51. Nagata Y, Hanagiri T, Mizukami M, Kuroda K, Shigematsu Y, Baba T, et al. Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan. Lung Cancer. 2009;65(1):91 ‑7. doi: 10.1016/j.lungcan.2008.10.012. 52. NCI Enterp rise Vocabulary Services. Common Terminology Criteria for Adverse Events (CTCAE). Available at: http://evs.nci.nih.gov/ftp1/CTCAE/ 53.